SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMC NEWS

TMCNET eNEWSLETTER SIGNUP

Global Intravenous Immunoglobulin (IVIg) Strategic Business Report 2017-2024 - Leading Players are CSL, Grifols & Shire - Research and Markets
[October 12, 2017]

Global Intravenous Immunoglobulin (IVIg) Strategic Business Report 2017-2024 - Leading Players are CSL, Grifols & Shire - Research and Markets


The "Intravenous Immunoglobulin (IVIg) - Global Strategic Business Report" report has been added to Research and Markets' offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

The report profiles 24 companies including many key and niche players such as:

  • Bharat Serums and Vaccines Limited (India)
  • Biotest AG (Germany)
  • China Biologic Products, Inc. (China)
  • CSL Limited (Australia)
  • Grifols, S.A. (Spain)
  • Guizhou Taibang Biological Products Co., Ltd (China)
  • Hualan Biological Engineering Inc. (China)
  • Kedrion S.p.A. (Italy)
  • LFB Group (France)
  • Octapharma AG (Switzerland)
  • Shanghai RAAS Blood Products Co., Ltd. (China)
  • Shire plc (Ireland)
  • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd (China)

Key Topics Covered:

1. INDUSTRY OVERVIEW

Immunoglobulins to See Steady Growth

Intravenous Immunoglobulin

A Proliferating Biologic

Application Areas

A Brief Review

Market Outlook

Growth Drivers and Market Challenges

Competitive Scenario

Grifols Continues to Consolidate Market Position

Comparison of Select Drugs and Approved Indications

CSL Sees Robust Growth in Immunoglobulin Franchise

Shire Continues to Invest Big in Immunoglobulins

Bivigam Changes Hands Consequent to Unexpected Turn of Events

2. MARKET TRENDS

Strong Demand from Major Indications and Pipeline SCIg Products to Fuel Growth of Immunoglobulins

Increasing Awarenes of Primary Immunodeficiency Disease to Drive IVIg Market

The Mainstay of PI Therapy

Subcutaneous IG Formulations Gain Therapeutic Foothold


Hyperimmune Globulin

Taking IVIg Therapy a Step Ahead

Unsuccessful Clinical Trials for Alzheimer's

A major Setback for IVIg Market

Synthetic Replacements to IVIg Therapy

IVIg Therapy

Home-based vs. Outpatient Settings

Per Capita Consumption Rate Varies Across Countries

Favorable Reimbursement and High Usage make US the Largest Consumer

Growing Adoption of Screening Programs to Reduce Usage of Immunoglobulins in the Treatment of SCID

Aging Global Population: Major Opportunity Indicator

Improving Healthcare Expenditure to Foster Growth

3. PLASMA PROTEINS - AN OVERVIEW

Plasma and Plasma Derivatives Continue to Dominate Blood Components Market

Regulations Exercise a Tight Rein over Plasma Therapy & Immunoglobulins

4. THERAPY OVERVIEW

Immunoglobulins Overview

IVIg and SCIg: A Face-off!

Cost of Product and Treatment

Side-Effects

Frequency of Treatment

Safety Considerations

Patient Response to Treatment Varies

Site of Care

IVIg Therapy Introduction

Intravenous Immunoglobulin

Mechanism of IVIg Action

IVIg Dosage and Treatment Response Time

Common IVIg Intravenous Dosing Recommendations by Indication

Complications and Side Effects of Using IVIg

Precautions to be Undertaken

Intravenous Immunoglobulin

Indications

FDA Approved Indications for IVIg

Off-Label Usage of IVIg

Select Off-Label Indications for IVIg

Applications by Medical Specialty

Neurology

Hematology

Immunology

Dermatology

Nephrology, Rheumatology, Ophthalmology, and Other Diseases

5. RECENT INDUSTRY ACTIVITY

LFB Group's 10% IVIg Gains More Approvals in Europe

CSL Acquires Majority Stake in Ruide

Baxter Acquires Claris Injectables

ADMA Biologics Takes Over BTBU

Green Cross Receives FDA Complete Response Letter for IVIG-SN

China Biologic Products Completes Acquisition of Guizhou Taibang

ProMetic Completes Patient Enrolment for Phase III Pivotal IVIG Trial

Kroger Combines Axium Pharmacy and Modern HC

Shire Acquires Baxalta

FDA Accepts BLA for IVIG-SN from Green Cross

Kedrion Bags US Commercial Rights to BIVIGAM

China Biologic Products to Commence Clinical Trials on Next- Gen IVIG Products

FDA Clears ProMetic's IND for IVIg

LFB Obtains Initial Market Authorizations for 10% Liquid IVIg in Europe

Baxter Divests its BioScience Division

Emergent BioSolutions Acquires Cangene

CMS Begins Evaluation of Payment for In-home IVIG Administration

6. FOCUS ON (News - Alert) SELECT PLAYERS

7. GLOBAL MARKET PERSPECTIVE

Total Companies Profiled: 24 (including Divisions/Subsidiaries 32)

  • The United States (11)
  • Canada (2)
  • Japan (1)
  • Europe (8)
    • France (1)
    • Germany (1)
    • The United Kingdom (2)
    • Italy (1)
    • Spain (1)
    • Rest of Europe (2)
  • Asia-Pacific (Excluding Japan) (9)
  • Latin America (1)

For more information about this report visit https://www.researchandmarkets.com/research/pvm6jk/intravenous


[ Back To TMCnet.com's Homepage ]






Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2017 Technology Marketing Corporation. All rights reserved | Privacy Policy